Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Simcere Pharmaceutical Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013625
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Simcere Pharmaceutical Group (Simcere) is a drug discovery company that manufactures and supplies branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas including anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, and others. Its products include recombinant human endostatin injection, nedaplatin for injection, palonosetron hydrochloride injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, neurology, infectious diseases, anti-inflammation and cardiovascular disease. The company conducts research and development to develop new drugs. It partners with pharma companies to develop novel anti-VEGF humanized monoclonal antibody. Simcere is headquartered in Nanjing, China.

Simcere Pharmaceutical Group – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Simcere Pharmaceutical Group, Medical Devices Deals, 2011 to YTD 2017 10
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Amgen and Simcere Pharma Enter into Co-Development Agreement 12
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 13
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 15
Simcere Pharma Enters Into Co-Development Agreement With Suzhou NeuPharma 16
Simcere Pharma Enters Into Co-Development Agreement With Nanjing Medical University 17
Equity Offering 18
Simcere Pharma May Raise up to USD128.9 Million in Public Offering of Shares 18
Acquisition 19
Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For US$517 Million In Going Private Transaction 19
Zhuhai Rongding To Acquire Jilin Boda Pharma From Simcere Pharma For US$65 Million 21
Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For US$48 Million 22
Simcere Pharmaceutical Group – Key Competitors 23
Simcere Pharmaceutical Group – Key Employees 24
Simcere Pharmaceutical Group – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Corporate Communications 27
Aug 02, 2016: Simcere Pharma announced appointment of D.r Hua Mu as Chief Officer of Science and President on Research and Development 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Key Facts 2
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Simcere Pharmaceutical Group, Deals By Therapy Area, 2011 to YTD 2017 8
Simcere Pharmaceutical Group, Medical Devices Deals, 2011 to YTD 2017 10
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Amgen and Simcere Pharma Enter into Co-Development Agreement 12
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 13
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 15
Simcere Pharma Enters Into Co-Development Agreement With Suzhou NeuPharma 16
Simcere Pharma Enters Into Co-Development Agreement With Nanjing Medical University 17
Simcere Pharma May Raise up to USD128.9 Million in Public Offering of Shares 18
Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For US$517 Million In Going Private Transaction 19
Zhuhai Rongding To Acquire Jilin Boda Pharma From Simcere Pharma For US$65 Million 21
Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For US$48 Million 22
Simcere Pharmaceutical Group, Key Competitors 23
Simcere Pharmaceutical Group, Key Employees 24
Simcere Pharmaceutical Group, Subsidiaries 25

★海外企業調査レポート[Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aurobindo Pharma Ltd (AUROPHARMA):製薬・医療:M&Aディール及び事業提携情報
    Summary Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API's). Its products portfolio includes active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, ga …
  • LegoChem Biosciences Inc (141080)-製薬・医療分野:企業M&A・提携分析
    Summary LegoChem Biosciences Inc (LCB) is a drug company that research and develops small molecule drugs. The company’s services include joint and contract research, chemical library package, compound synthesis and sales, and screening services. Its screening services include metabolic stability, pl …
  • Banco Pan S.A. (BPAN4):企業の財務・戦略的SWOT分析
    Banco Pan S.A. (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Genesis Energy LP (GEL):企業の財務・戦略的SWOT分析
    Genesis Energy LP (GEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Zydus Wellness Ltd (ZYDUSWELL):企業の財務・戦略的SWOT分析
    Zydus Wellness Ltd (ZYDUSWELL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Foundation Medicine Inc (FMI):企業の財務・戦略的SWOT分析
    Summary Foundation Medicine Inc (Foundation Medicine) is a molecular information products provider. The company provides molecular information and cancer research programs. It offers clinical products such as FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers, or hematolog …
  • MOL Hungarian Oil and Gas Plc (MOL):企業の財務・戦略的SWOT分析
    MOL Hungarian Oil and Gas Plc (MOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Pieridae Energy Ltd (PEA):石油・ガス:M&Aディール及び事業提携情報
    Summary Pieridae Energy Ltd (Pieridae Energy), formerly Petrolia Inc, is an oil and gas company that develops, explores, and produces oil resources. The company’s projects comprise Haldimand project, Bourque project, Tar Point project, Corte-Real project, Anticosti project, Dalhousie project; Edgar, …
  • ContourGlobal plc (GLO):企業の財務・戦略的SWOT分析
    ContourGlobal plc (GLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • G-III Apparel Group Ltd (GIII):企業の財務・戦略的SWOT分析
    Summary G-III Apparel Group, Ltd. (G-III or “the company”) is an apparel and footwear manufacturing company. The company designs, manufactures and markets outerwear, dresses, sportswear, swimwear, women's suits and performance wear, luggage, footwear, and women's handbags, leather goods, and cold we …
  • Meggitt Training Systems, Inc.:企業の戦略・SWOT・財務分析
    Meggitt Training Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Meggitt Training Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • CHC Group Ltd:企業の戦略的SWOT分析
    CHC Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Kemwell Biopharma Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Kemwell Biopharma Pvt Ltd (Kemwell) formerly Kemwell Pvt Ltd a subsidiary of Recipharm AB is a healthcare solutions provider that offers product development and manufacturing solutions. The organization provides contract pharmaceutical development and manufacturing organization and concentra …
  • Bancolombia SA (BCOLOMBIA):企業の財務・戦略的SWOT分析
    Bancolombia SA (BCOLOMBIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Siemens AG (SIE):企業の財務・戦略的SWOT分析
    Siemens AG (SIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Altadis USA Inc:企業の戦略・SWOT・財務情報
    Altadis USA Inc - Strategy, SWOT and Corporate Finance Report Summary Altadis USA Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Canam Group Inc:企業の戦略的SWOT分析
    Canam Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Cogent Communications Holdings inc (CCOI):企業の財務・戦略的SWOT分析
    Cogent Communications Holdings inc (CCOI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Federal Electricity & Water Authority:電力:M&Aディール及び事業提携情報
    Summary Federal Electricity & Water Authority (FEWA) owned by the Ministry of Electricity and Water, is an energy utility that produces electricity and distillates sea water. It generates electricity from natural gas; and distillates water in multiple effect distillation (MED) and reverse osmosis (R …
  • Synthetic Genomics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Synthetic Genomics Inc (Synthetic Genomics) is a provider of synthetic biology and synthetic genomics solutions. The company provides DNA synthesis services, instrumentation, reagents, and bioinformatics services and software packages, among others. It provides solutions in genomics research …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆